Representing 18% of all business expenditure on R&D in the UK, the biopharmaceutical industry remains the highest R&D spending sector, (£4.3 billion in 2017).

It is critical that the core biopharmaceutical industry, in particular, is also seen as a key partner in achieving the Government’s target to boost spending on R&D, increasing investment to 2.4% of GDP by 2027 and 3% longer-term.